Nath Bio-Genes (India) Ltd
NATHBIOGEN NSE
Nath Bio-Genes (India) Ltd
FMCGNSE: NATHBIOGEN BSE: 537291 Agricultural Products
Key Fundamentals
MicrocapAgricultural ProductsFMCGMarket Cap
₹300 Cr
Volatility
Moderate
P/E Ratio
7.6
EBITDA
₹52.44 Cr
Return on Equity
5.99%
Debt to Equity
0.2
Book Value
₹358.06
52W High
₹204
52W Low
₹126.15
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nath Bio-Genes (India) Ltd insights
46 extracted metrics + investor summaries across FY12–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Stock is trading at 0.43 times its book value
- Debtor days have improved from 110 to 70.0 days.
Weaknesses
5- Tax rate seems low
- Company has a low return on equity of 5.93% over last 3 years.
- Contingent liabilities of Rs.89.3 Cr.
- Earnings include an other income of Rs.15.2 Cr.
- Dividend payout has been low at 9.52% of profits over last 3 years
Growth Rate
Revenue Growth
20.46% ↘
Net Income Growth
7.85% ↘
Cash Flow Change
-76.43% ↘
ROE
-7.85% ↗
ROCE
-5.73% ↘
EBITDA Margin (Avg.)
-22.30% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 235 | 23 | 32 | 43 | 244 | 32 | 37 | 52 | 284 | 44 | 66 | 52 | 328 |
| Expenses | 198 | 18 | 26 | 39 | 207 | 27 | 29 | 52 | 254 | 38 | 62 | 47 | 293 |
| Operating Profit | 37 | 5 | 6 | 4 | 37 | 5 | 8 | 0 | 29 | 6 | 4 | 4 | 35 |
| OPM % | 16% | 22% | 18% | 9% | 15% | 15% | 22% | 0.8% | 10% | 14% | 5% | 9% | 11% |
| Other Income | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 3 | 2 | 3 | 1 | 2 | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 34 | 2 | 5 | 3 | 34 | 1 | 4 | 2 | 29 | 5 | 2 | 2 | 33 |
| Tax % | 1% | 19% | 17% | 19% | 1% | -3% | 30% | 30% | 2% | 12% | 35% | 100% | 2% |
| Net Profit | 33 | 2 | 4 | 3 | 33 | 1 | 3 | 1 | 28 | 5 | 2 | 0 | 32 |
| EPS in Rs | 17.59 | 0.79 | 2.02 | 1.38 | 17.55 | 0.58 | 1.39 | 0.78 | 14.88 | 2.54 | 0.84 | -0.01 | 16.98 |
Profit & Loss
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 97 | 109 | 230 | 234 | 248 | 268 | 445 | 490 |
| Expenses | 82 | 89 | 193 | 185 | 198 | 217 | 393 | 440 |
| Operating Profit | 15 | 20 | 37 | 49 | 50 | 51 | 52 | 49 |
| OPM % | 15% | 18% | 16% | 21% | 20% | 19% | 12% | 10% |
| Other Income | 1 | 1 | -87 | 1 | 4 | 4 | 14 | 15 |
| Interest | 2 | 4 | 11 | 10 | 9 | 11 | 16 | 17 |
| Depreciation | 5 | 5 | 3 | 3 | 3 | 4 | 4 | 4 |
| PBT | 9 | 12 | -63 | 36 | 42 | 41 | 46 | 43 |
| Tax % | -1% | 4% | 6% | 3% | 5% | 5% | 10% | — |
| Net Profit | 9 | 12 | -67 | 35 | 40 | 39 | 42 | 39 |
| EPS in Rs | 5.75 | 7.34 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 | 20.35 |
| Div. Payout % | 0% | 0% | -6% | 11% | 10% | 10% | 9% | — |
Balance Sheet
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 30 | 41 | 523 | 554 | 591 | 625 | 661 |
| Borrowings | 11 | 19 | 93 | 105 | 110 | 123 | 138 |
| Other Liabilities | 63 | 82 | 105 | 114 | 160 | 259 | 278 |
| Total Liabilities | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
| Fixed Assets | 21 | 38 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 5 | 5 | 6 | 6 | 6 |
| Other Assets | 99 | 121 | 490 | 543 | 625 | 770 | 842 |
| Total Assets | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
Cash Flow
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | — | — | 17 | 38 | 75 | 18 | -13 |
| Investing | — | — | -20 | -3 | -27 | -4 | 3 |
| Financing | — | — | -22 | -2 | -8 | -2 | -4 |
| Net Cash Flow | — | — | -25 | 34 | 39 | 11 | -13 |
| Free Cash Flow | — | — | 16 | 36 | 48 | 10 | -16 |
| CFO/OP | — | — | 54 | 80 | 150 | 37 | -22 |
Ratios
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 70 | 136 | 152 | 139 | 121 | 70 |
| Inventory Days | 587 | 667 | — | 4,388 | — | — | — |
| Days Payable | 146 | 239 | — | 586 | — | — | — |
| Cash Conversion Cycle | 487 | 499 | 136 | 3,954 | 139 | 121 | 70 |
| Working Capital Days | 79 | 64 | 427 | 415 | 342 | 321 | 253 |
| ROCE % | — | 24% | — | 7% | 7% | 7% | 7% |
Documents
1
Board Meeting Outcome for Outcome Of Board Meeting
4 May - FY26 audited results, Rs 2 dividend, independent director reappointed, MD pay raised to Rs 1.44 crore. 4 May - FY26 audited results, Rs 2 dividend, independent director reappointed, MD pay raised to Rs 1.44 crore.
2
Announcement under Regulation 30 (LODR)-Investor Presentation
4 May - Investor Presentation on Financial Results as on 31st March 2026 4 May - Investor Presentation on Financial Results as on 31st March 2026
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
11h - Company confirms it is not a large corporate as of 31 March 2026; outstanding long-term borrowing nil. 11h - Company confirms it is not a large corporate as of 31 March 2026; outstanding long-term borrowing nil.
4
NBIL Concall
10h - Audio recording of 5 May 2026 conference call on audited Q4 and FY26 results uploaded. 10h - Audio recording of 5 May 2026 conference call on audited Q4 and FY26 results uploaded.
5
Intimation Of Conference Call
29 Apr - Nath Bio-Genes Q4 & FY26 earnings conference call on 5 May 2026 at 4:00 PM IST. 29 Apr - Nath Bio-Genes Q4 & FY26 earnings conference call on 5 May 2026 at 4:00 PM IST.
Frequently Asked Questions about Nath Bio-Genes (India) Ltd
What does Nath Bio-Genes (India) Ltd do?
Incorporated in 1993, Nath Bio-Genes Ltd
is in the business of Production, Processing,
and Marketing of Hybrid and GM Seeds[1]
Where is Nath Bio-Genes (India) Ltd (NATHBIOGEN) listed?
Nath Bio-Genes (India) Ltd is listed on the Indian stock exchanges. It is listed on NSE: NATHBIOGEN and BSE: 537291. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Nath Bio-Genes (India) Ltd belong to?
Nath Bio-Genes (India) Ltd operates in the FMCG sector within the Agricultural Products industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a market capitalisation of approximately ₹300.26 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Nath Bio-Genes (India) Ltd?
The Price-to-Earnings (PE) ratio of Nath Bio-Genes (India) Ltd is 7.60. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Nath Bio-Genes (India) Ltd?
Over the past 52 weeks, Nath Bio-Genes (India) Ltd has traded between a low of ₹126.15 and a high of ₹204. This range helps investors understand the stock's price volatility and recent trading levels.
Does Nath Bio-Genes (India) Ltd pay dividends?
Yes, Nath Bio-Genes (India) Ltd has a dividend yield of 1.31%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a Return on Equity (ROE) of 5.99%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Nath Bio-Genes (India) Ltd on Tapetide?
On Tapetide, you can view Nath Bio-Genes (India) Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds[1]
Website nathbiogenes.com
CEO Mr. Satish Kagliwal
Employees 451
Listed 2014-01-28
Face Value ₹ 10
Issued Size 1,90,04,000